Low-Dose Semaglutide Treatment for Weight Loss and Heart Health in Obese Adult Pakistanis Without Type 2 Diabetes
Led by Asian Institute Of Medical Sciences · Updated on 2026-04-06
60
Participants Needed
1
Research Sites
13 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the efficacy and safety of low-dose semaglutide for weight loss and cardiometabolic improvement in obese Pakistani adults without type 2 diabetes. This pilot trial is open-label, single-arm, and conducted at a single center, aiming to provide local clinical evidence to support obesity management with semaglutide in this population. The study will enroll 60 adults aged 18 years or older with a BMI of 27.5 kgm or higher and no diagnosis of type 2 diabetes confirmed by blood tests.
Participants will receive once-weekly subcutaneous injections of semaglutide following a dose titration schedule 0.25 mg weekly for 4 weeks, 0.5 mg weekly for 4 weeks, and 1.0 mg weekly for 16 weeks, totaling 24 weeks of treatment. Alongside medication, all participants will receive standardized lifestyle counseling that includes a calorie-restricted diet with a 500-750 kcal daily deficit and at least 150 minutes of moderate-intensity physical activity weekly. This single-arm study does not include a placebo or comparator group.
Participants will undergo clinical and laboratory assessments at baseline, 12 weeks, and 24 weeks to monitor treatment effects and safety. Researchers will measure percentage changes in body weight as the primary outcome, alongside secondary outcomes including BMI, waist circumference, blood pressure, lipid profile, liver enzymes, and quality of life. Safety will be closely monitored through continuous tracking of adverse events and drug reactions. Data analysis will use statistical methods to evaluate changes over the study period, with participant confidentiality maintained throughout.
CONDITIONS
Brief Title
Low-Dose Semaglutide for Weight Loss in Obese Non-Diabetic Pakistani Adults
Research Team
F
Fatima Nadeem Dr, Pharm-D, Mphil
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Body mass index (BMI) of 27.5 kg/m² or greater according to WHO Asian cutoffs
No diagnosis of type 2 diabetes mellitus confirmed by fasting blood glucose less than 126 mg/dL and HbA1c less than 6.5% within three months prior to enrollment
Willingness and ability to provide written informed consent
Willingness to comply with study procedures, including weekly injections and lifestyle counseling
You will not qualify if you...
History of pancreatitis
History or presence of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2)
Pregnant or lactating women
Severe renal impairment (eGFR less than 30 mL/min/1.73 m²) or hepatic impairment (ALT or AST more than 3 times the upper limit of normal)
Current use of other anti-obesity medications
Known hypersensitivity to semaglutide or any component of the formulation
Any condition that may interfere with participation, adherence, or safety in the study as judged by the investigator
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Treatment
Duration - 24 weeks
Participants receive once-weekly subcutaneous injections of low-dose semaglutide following a dose titration schedule (0.25 mg weekly for 4 weeks, 0.5 mg weekly for 4 weeks, then 1.0 mg weekly for 16 weeks) along with standardized lifestyle counseling including a hypocaloric diet and physical activity guidance.
Baseline, 12-week, and 24-week visits for clinical and laboratory assessments
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Similar Trials
Virtual Nutrition Education to Prevent Weight Gain During Maintenance Chemotherapy in Children and Adolescents with Acute Lymphoblastic Leukemia
Study of Gene Expression in Tissues Related to Blood Sugar and Weight in Adults Undergoing Abdominal Surgery
Phase 1 Study of Single-Dose Semaglutide Nasal Spray to Assess Safety, Tolerability, and Pharmacokinetics in Adults with Overweight or Obesity Aged 18 to 65
Evaluating Multimodal Ultrasound to Monitor Muscle Mass in Metabolic Syndrome, Type 2 Diabetes, and Obesity
Reducing Obesity and Related Health Risks in Native American Employees at Twin Arrows Casino Using a Culturally Relevant Plant-Rich Diet
Study of Safety, Tolerability, and Effects of NNC0721-8060 Compared to Semaglutide and Placebo in Adults with Overweight or Obesity
Phase 12a Study Evaluating Safety and Effects of ARO-ALK7 in Adults With Obesity, With or Without Type 2 Diabetes
Master Protocol Evaluating Multiple Investigational Treatments for Chronic Weight Management in Adults with Obesity or Overweight
Evaluating a Digital Tool to Help Clinicians Prescribe Personalized Exercise for Adults with Cardiovascular Disease Risk Factors in a Randomized Crossover Trial
Testing a Responsive Parenting Program to Prevent Obesity in High-Risk Infants Through Pediatric Primary Care
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial.
Thomas A Wadden, Timothy S Bailey, Liana K Billings...
Beyond Glycemic Control: Concurrent GLP-1 Receptor Agonist Use Is Associated with Reduced Urinary Adverse Events Following OnabotulinumtoxinA Treatment in Non-Diabetic Adults with Overactive Bladder.
Muhammed A M Hammad, Sophia G Quesada, Aimee L Belczyk...
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.